Format

Send to

Choose Destination
Vaccine. 2020 Jan 16;38(3):427-432. doi: 10.1016/j.vaccine.2019.10.063. Epub 2019 Nov 1.

Impact of the adolescent pertussis booster dose on the incidence of pertussis in British Columbia and Quebec, Canada.

Author information

1
Risques biologiques et santé au travail, Institut national de santé publique du Québec, Québec G1V 5B3, Canada; Département de médecine sociale et préventive, Université Laval, Québec G1V 0A6, Canada. Electronic address: nicholas.brousseau.ciussscn@ssss.gouv.qc.ca.
2
Communicable Diseases and Immunization Service, BC Centre for Disease Control, Vancouver V5Z 4R4, Canada; School of Population and Public Health, Department of Medicine, University of British Columbia, Vancouver V6T 1Z3, Canada.
3
Département de médecine sociale et préventive, Université Laval, Québec G1V 0A6, Canada.
4
Risques biologiques et santé au travail, Institut national de santé publique du Québec, Québec G1V 5B3, Canada.
5
Communicable Diseases and Immunization Service, BC Centre for Disease Control, Vancouver V5Z 4R4, Canada.
6
Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal H3T 1J4, Canada; Division of Paediatric Infectious Diseases and Department of Medical Microbiology, CHU Sainte-Justine, Montreal H3T 1C5, Canada.
7
Public Health Laboratory, BC Centre for Disease Control, Vancouver V5Z 4R4, Canada; Department of Pathology and Laboratory Medicine, Department of Medicine, University of British Columbia, Vancouver V6T 2B5, Canada.
8
Risques biologiques et santé au travail, Institut national de santé publique du Québec, Québec G1V 5B3, Canada; Département de médecine sociale et préventive, Université Laval, Québec G1V 0A6, Canada.

Abstract

Impact of an adolescent tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine program was assessed in the provinces of British Columbia and Quebec, Canada. In both provinces, the Tdap booster has been in place since 2004, targeting Grade 9 students (14-15-years-of-age). Incidence rate ratios (IRRs) standardizing notification rates among teens 15-19-years-old to infants <1-year-old decreased following introduction of the Tdap program and were significantly halved during the 2009-2012 post-Tdap versus 2000-2003 pre-Tdap period. This program impact, however, is tempered by the observation that pertussis incidence among 15-19-year-olds was already lower than any other pediatric age group, following gradual decline from pre-teen rates even before the Tdap program. The risk of hospitalization among adolescents 15-19-years-old was also low throughout at <1/100,000. Furthermore, IRRs increased in 2013-2017 when an increasing proportion of 15-19-year-olds were primed with acellular pertussis vaccine only, suggesting short-lived Tdap booster-dose effectiveness that warrants further monitoring.

KEYWORDS:

Acellular pertussis vaccine; Adolescent booster dose; Immunization; Pertussis; Vaccination; Whooping cough

PMID:
31685295
DOI:
10.1016/j.vaccine.2019.10.063
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center